Become a member ✅ Subscribe to STAT+ to access premium benefits

Our December STAT+ benefits include discounts on events and access to our premium data tools. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

www.statnews.com/stat-plus Subscribe to STAT+ and access exclusive benefits this month When you're a STAT+ subscriber, you get to enjoy perks like discounts on our STAT Reports and events, free access to premium data tools like our CRISPR TRACKR, as well as in-depth daily coverage and analysis of the life sciences. JOIN STAT+ STAT in NYC: A Look Ahead at Biotech in 2023 Date: December 5, 2022 @ 6pm Location: Convene (237 Park Ave, New York) Tonight, join the STAT biotech team and industry insiders as they take the temperature of the biggest regulatory and financial issues facing the industry. Enjoy cocktails, networking, and thoughtful discussion unpacking the latest innovations.  Use code THANKS15 for 15% off your in-person or virtual pass. Register The future of messenger RNA: Covid vaccines were just the beginning Messenger RNA, the same genetic material that pharmaceutical companies quickly harnessed to develop game-changing Covid-19 vaccines, is opening up a world of possibilities, and arming doctors with new tools to prevent or combat disease. In this report, STAT, the most authoritative source for reporting on innovations in health care and biotech, delves into the potential of mRNA. For a limited time, get 50% off STAT Reports with code REPORT50.   Purchase A conversation with Otis Brawley Date: December 6, 2022 @ 2pm Virtual A luminary in the battle against cancer, Brawley leads an effort at Johns Hopkins to study and eliminate racial disparities in cancer prevention, detection, and treatment. In this conversation, he'll unpack the work he is doing to build a more equitable future for cancer care.   Register STAT@JPM: What’s Next For Biotech? Date: January 9, 2023 from 6pm–9pm PT Location: Lower level at The Hibernia, San Francisco As we cautiously emerge from the pandemic to meet in person, the STAT biotech team will be in San Francisco to help you digest all the biggest stories from the year's biggest investor conference. Enjoy some cocktails and expect some big-name guests to stop by as well.   Sign Up MOLLY FERGUSON/STAT Adam's Take: Northwest Bio study of brain cancer vaccine still falls short By Adam Feuerstein Data involving the treatment called DCVax might appear to be encouraging, but but the survival benefit was derived from an untrustworthy, post-hoc analysis that was implemented and conducted after the study had already been completed. Read more STAT+ Reads Check out our recent top stories: PhRMA, once invincible in Washington, has lost its edge by Rachel Cohrs Following your gut: How scientists are getting closer to linking the microbiome and chronic diseases by Isabella Cueto Unexpected troubles hit large medical billing firm R1 RCM, part-owned by Ascension by Bob Herman Boom and bust: Whose biotech VC assets have grown and shrunk the most? by Allison DeAngelis and Kate Sheridan Read more Monday, December 5, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser